Literature DB >> 10985961

Decreased expression of thioredoxin and glutaredoxin in placentae from pregnancies with pre-eclampsia and intrauterine growth restriction.

L Sahlin1, E Ostlund, H Wang, A Holmgren, G Fried.   

Abstract

Pre-eclampsia is one of the major contributors to perinatal morbidity. This study was performed to test a hypothesis which suggests that pre-eclampsia is associated with inadequate control by the thioredoxin system and other related reducing systems. Placental tissue from normal pregnancies (NC), severe pre-eclampsia with fetuses small for gestational age (SPE), mild pre-eclampsia with fetuses small for gestational age (MPE) and pregnancies with small fetuses for gestational age without any sign of pre-eclampsia (IUGR) was collected immediately after delivery. The mRNA levels for thioredoxin and glutaredoxin were determined using a solution hybridization method and the distribution of the proteins in a normal placenta was analysed by immunohistochemistry. Results showed that the thioredoxin mRNA level in the SPE group was decreased to one third of the level in the NC group. Also the IUGR group showed a significant decrease. The glutaredoxin mRNA level in the SPE group was one half of that seen in the NC group. There was significant correlation between the mRNA levels for thioredoxin and glutaredoxin, both in the normal and growth restricted pregnancies. We conclude that the thioredoxin and glutaredoxin reducing systems are affected in placenta from pregnancies with pre-eclampsia and/or growth restriction of fetuses, and that the decrease correlates to the severity of the condition. Copyright 2000 Harcourt Publishers Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10985961     DOI: 10.1053/plac.2000.0554

Source DB:  PubMed          Journal:  Placenta        ISSN: 0143-4004            Impact factor:   3.481


  7 in total

1.  In vitro ischemia-reperfusion injury in term human placenta as a model for oxidative stress in pathological pregnancies.

Authors:  T H Hung; J N Skepper; G J Burton
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

2.  Dynamic thiol-disulfide homeostasis in hyperemesis gravidarum.

Authors:  M Ergin; B D Cendek; S Neselioglu; A F Avsar; O Erel
Journal:  J Perinatol       Date:  2015-07-09       Impact factor: 2.521

3.  Interplay between vascular endothelial growth factor (VEGF) and nuclear factor erythroid 2-related factor-2 (Nrf2): implications for preeclampsia.

Authors:  Nisreen Kweider; Athanassios Fragoulis; Christian Rosen; Ulrich Pecks; Werner Rath; Thomas Pufe; Christoph Jan Wruck
Journal:  J Biol Chem       Date:  2011-10-27       Impact factor: 5.157

4.  Overexpression of thioredoxin-1 reduces oxidative stress in the placenta of transgenic mice and promotes fetal growth via glucose metabolism.

Authors:  Takashi Umekawa; Takashi Sugiyama; Tomohisa Kihira; Nao Murabayashi; Lingyun Zhang; Kenji Nagao; Yuki Kamimoto; Ning Ma; Junji Yodoi; Norimasa Sagawa
Journal:  Endocrinology       Date:  2008-05-01       Impact factor: 4.736

5.  The expression of thioredoxin-1 in preterm delivery placenta.

Authors:  Junying Song; Xudong Dong; Yan Chen; Guixian Chen; Hong Liang; Hajime Nakamura; Junji Yodoi; Jie Bai
Journal:  Redox Rep       Date:  2012       Impact factor: 4.412

6.  Evaluation of the Effect of the Fibroblast Growth Factor Type 2 (FGF-2) Administration on Placental Gene Expression in a Murine Model of Preeclampsia Induced by L-NAME.

Authors:  Margarita L Martinez-Fierro; Idalia Garza-Veloz; Maria Eugenia Castañeda-Lopez; Dorothy Wasike; Claudia Castruita-De la Rosa; Iram Pablo Rodriguez-Sanchez; Ivan Delgado-Enciso; Jose Flores-Mendoza
Journal:  Int J Mol Sci       Date:  2022-09-04       Impact factor: 6.208

Review 7.  Placental endoplasmic reticulum stress and oxidative stress in the pathophysiology of unexplained intrauterine growth restriction and early onset preeclampsia.

Authors:  G J Burton; H-W Yung; T Cindrova-Davies; D S Charnock-Jones
Journal:  Placenta       Date:  2008-12-09       Impact factor: 3.481

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.